Suzhou Thery’s Generic Nilotinib Approved by China’s NMPA
China-based Suzhou Thery Pharmaceutical Inc. has announced that the National Medical Products Administration (NMPA) has...
Novartis
CANbridge Secures Global Rights to Second-Generation Gene Therapy for SMA
China – based biopharma CANbridge Pharmaceuticals Inc. (HKG: 1228) has unveiled a license deal to...
Novartis China Establishes Health Development Fund in Boao Lecheng
Novartis (NYSE: NVS) China has announced the establishment of a health development fund, a significant...
Fudan Team Presents Ribociclib Phase II Bridging Study Results at ESMO Asia
A Fudan University Shanghai Cancer Center team led by Shao Zhimin made an oral presentation...
Novartis Partners with Sinopharm for Commercial Promotion of Gleevec and Exjade in China
Swiss giant Novartis (NYSE: NVS) entered into a promotion agreement with China-based Sinopharm Group Co.,...
Novartis Considers Sale of Non-Core Units to Fund Innovation
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) is reportedly considering the sale of certain ‘non-core’...
Novartis Partners with Alibaba Health to Enhance Patient Medication Accessibility
The 5th China International Import Expo (CIIE) saw the announcement of a partnership between Swiss...
Novartis’ Cosentyx Gains Approval for New Doses in China
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced receiving marketing approval for two new specifications...
Novartis Expands Strategic Collaboration with Bo’Ao Lecheng Pilot Zone
Novartis (NYSE: NVS) announced a further strategic collaboration with the Bo’Ao Lecheng Medical Tourism Pilot...
Innovent’s Parsaclisib Filed for Marketing Approval in China
China’s Center for Drug Evaluation (CDE) has received a marketing approval application for Innovent Biologics...
Novartis Q3 Revenues Rise 4% YOY; China Sales Expand Despite COVID Lockdowns
Swiss pharmaceutical giant Novartis (NYSE: NVS) has reported a 4% year-on-year (YOY) increase in global...
HEC Pharma Overturns Patent Decision Against Novartis’ Gilenya
China-based generics firm HEC Pharma has managed to overturn a previous final decision in a...
Novartis Faces Setback in US Patent Battle Over Multiple Sclerosis Drug Gilenya
Swiss pharmaceutical giant Novartis AG (SWX: NOVN) has encountered its latest and potentially final setback...
Huahai Pharmaceutical Gains FDA Approval for Generic Fingolimod
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received Abbreviated New...
Shanghai Pharma’s CD20 Antibody Advances to Primary Nephropathy Trial After NMPA Approval
China’s Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has received approval from the National Medical Products...
Novartis Partners with Beijing’s Changping District to Expand Drug Development
Swiss pharma giant Novartis (NYSE: NVS) has partnered with Beijing’s Changping district government to expand...
Novartis to Spin Off Sandoz, Focus on Innovative Drugs
Swiss drugmaker Novartis announced plans to spin off its generic and biosimilar unit, Sandoz, to...
Novartis Aims for China to Be Second – Largest Market by 2024
Dan Brindle, head of Novartis AG’s (NYSE: NVS) China operations, recently spoke with Xinhua news...
Sunshine Guojian’s SSGJ-608 Hits Primary Endpoint in Psoriasis Study
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced...
Transcenta Appoints Dr. Caroline Germa as Global Drug Development Chief
China-based biotech Transcenta Holdings Ltd (HKG: 6628) announced the appointment of Dr. Caroline Germa as...